{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:06:53Z","timestamp":1784909213985,"version":"3.55.0"},"reference-count":106,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,6,12]]},"DOI":"10.1080\/14656566.2024.2373354","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T14:51:10Z","timestamp":1719327070000},"page":"1187-1198","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond"],"prefix":"10.1080","volume":"25","author":[{"given":"Antonio","family":"Portarapillo","sequence":"first","affiliation":[{"name":"Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nello","family":"Tommasino","sequence":"additional","affiliation":[{"name":"Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lauletta","sequence":"additional","affiliation":[{"name":"Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Feo","sequence":"additional","affiliation":[{"name":"Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Salsano","sequence":"additional","affiliation":[{"name":"Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-050X","authenticated-orcid":false,"given":"Fabrizio","family":"Martora","sequence":"additional","affiliation":[{"name":"Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[{"name":"Rheumatology Research Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18245"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3384"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207488"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14139"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2287"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.01.014"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637829"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3386"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00977-1"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2173170"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2173171"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713313"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.049"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.087"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"e_1_3_6_19_1","volume-title":"Canadian guidelines for the management of plaque psoriasis","author":"Canadian Psoriasis Guidelines Committee","year":"2009","unstructured":"Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. Ottawa (ON): Canadian Dermatology Association; 2009."},{"issue":"4","key":"e_1_3_6_20_1","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim WB","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017 Apr;63(4):278\u2013285.","journal-title":"Can Fam Physician"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7240.963"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12790"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00536-6"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4029"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.044"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/PHMT.S389108"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.08.026"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1996.tb00142.x"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.050"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0198-x"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0718"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2009.09007"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2218086"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S402183"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1243843"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093233"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15543"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2160447"},{"issue":"2","key":"e_1_3_6_40_1","first-page":"101","article-title":"Efficacy and safety of adalimumab in Crohn\u2019s disease","volume":"90","author":"Serghini M","year":"2012","unstructured":"Serghini M, Haddad W, Jeddi H, et al. Efficacy and safety of adalimumab in Crohn\u2019s disease. Tunis Med. 2012 Feb;90(2):101\u2013107.","journal-title":"Tunis Med"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S252578"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00578-0"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.622934"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S146004"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2023.59.3.3419557"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2263108"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112297"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15667"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15030"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.20.06684-5"},{"key":"e_1_3_6_52_1","unstructured":"Summary of product characteristics. Available from [cited 2024 Jan 7]. Available from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_it.pdf"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15093"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2445"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16740"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_3_6_59_1","unstructured":"SPEVIGO\u00ae (spesolimab-sbzo) injection for intravenous use: highlights of prescribing information. 2022 Sep [cited 2023 Oct 22]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761244s000lbl.pdf"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01801-4"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1811317"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043666"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01378-8"},{"key":"e_1_3_6_64_1","unstructured":"ClinicalTrials.gov. EffisayilTM ON: a study to test long-term treatment with spesolimab in people with generalized pustular psoriasis who took part in a previous study. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03886246"},{"key":"e_1_3_6_65_1","unstructured":"ClinicalTrials.gov. An expanded access trial in Japan to provide spesolimab to people with a flare-up in generalized pustular psoriasis who have no other treatment options. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05200247"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21743"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00120-0"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107008"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2230122"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308713"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2018.09.042"},{"key":"e_1_3_6_72_1","unstructured":"Takeda Takeda to Acquire Late-Stage Potential Best-in-Class Oral Allosteric TYK2 Inhibitor NDI-034858 from Nimbus Therapeutics. Takeda. 2022 [cited 2024 Jan 5]."},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00600"},{"key":"e_1_3_6_74_1","unstructured":"Takeda Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279 an Oral Once-Daily TYK2 Inhibitor in People with Moderate to Severe Plaque Psoriasis. Takeda. 2023."},{"key":"e_1_3_6_75_1","volume-title":"Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update Ventyx Biosciences","author":"Patti Bank","year":"2023","unstructured":"Patti Bank. Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update Ventyx Biosciences. Encinitas (CA) (USA); 2023. https:\/\/ir.ventyxbio.com\/news-releases\/news-release-details\/ventyx-biosciences-announces-results-phase-2-trial-vtx958\/"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01698"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1512404"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S433367"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad083"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01210"},{"key":"e_1_3_6_81_1","unstructured":"Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects with Moderate to Severe Plaque Psoriasis (IMPACT-PS). Identifier NCT03832738. U.S. National Library of Medicine; 2019 [cited 2024 Apr 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03832738"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2023.05.009"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1602142"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1037983"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3185"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00422"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00632-7"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_309_23"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01068-x"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020239"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15204"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15632"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1288"},{"key":"e_1_3_6_94_1","volume-title":"Soligenix announces top-line results of the phase 2a study of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. PR Newswire: press release distribution, targeting, monitoring and marketing","author":"Soligenix Inc","unstructured":"Soligenix Inc. Soligenix announces top-line results of the phase 2a study of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. PR Newswire: press release distribution, targeting, monitoring and marketing. 2024 Jan 4. https:\/\/www.prnewswire.com\/news-releases\/soligenix-announces-top-line-results-of-the-phase-2a-study-of-sgx302-synthetic-hypericin-in-patients-with-mild-to-moderate-psoriasis-302025994.html"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15779"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe2888"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.11.032"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.03.020"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13707"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24071388"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-021-00324-1"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1839007"},{"key":"e_1_3_6_104_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121746"},{"key":"e_1_3_6_105_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_871_22"},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.009"},{"key":"e_1_3_6_107_1","first-page":"llae162","article-title":"Efficacy of JAK inhibitors in the treatment of psoriasiform atopic dermatitis","author":"Napolitano M","unstructured":"Napolitano M, Foggia L, Patruno C, et al. Efficacy of JAK inhibitors in the treatment of psoriasiform atopic dermatitis. Clin Exp Dermatol. llae162","journal-title":"Clin Exp Dermatol"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2373354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T22:54:55Z","timestamp":1727218495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2373354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":106,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,6,12]]}},"alternative-id":["10.1080\/14656566.2024.2373354"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2373354","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}